Remidio Launches its new device ‘Pristine’, Innovating AI-Powered Eye Diagnostics with Dual Brand Strategy

Pristine Sets New Benchmark in In-Clinic Diagnostics with Multi-Modality Precision and Seamless Workflow

Bangalore, India – May 21, 2025 — After a decade of transforming access to eye care in India and beyond, Remidio Innovative Solutions announces a pivotal evolution in its journey, the launch of its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics.

The New Brand Architecture

• Remidio: “Remidio remains the mother brand, synonymous with its mission of eliminating preventable blindness through simplicity and innovation and advancing healthcare through the eye.

• Insta represents portable devices for outreach and primary screening to bring more people into care pathways.

• Pristine is dedicated to in-clinic, multi-modality devices that drive efficiency, precision, and deliver a seamless, high-performance diagnostic workflow.

Together, these brands serve the complete care continuum, from screening to diagnosis, from detection to decision-making.

Over the past decade, Remidio has focused on expanding access to eye care. Through portable technology and AI, the company has facilitated over 16 million screenings across 40+ countries, addressing low awareness and limited access to early detection. Its Insta series of portable tools for frontline workers has built an ecosystem that now directs millions more patients to ophthalmology clinics annually.

With more patients arriving for specialist evaluation, the next challenge is clear, delivering faster, smarter, and more efficient clinical care. The company’s new brand, Pristine, is a natural progression of this mission, extending Remidio’s impact from outreach to advanced in-clinic diagnostics.

Why Now?

“Having built tools that enabled early detection and brought more patients to specialists, the next step was inevitable, improving the efficiency of care once they arrive,” said Dr. Anand Sivaraman, Founding Director and CEO of Remidio. “With Pristine, we’re equipping clinics to see more, do more, not just faster, but with greater clinical confidence.”

Pristine’s suite of in-clinic innovations is built to drive measurable efficiency.

• Pristine 1.5 reduces retina imaging time per patient through automated workflows.

• Pristine 5.0 offers true-color, wide-field imaging in seconds, maximizing throughput without compromising quality.

• The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care.

• The soon to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.

Together, these devices enable clinics to ‘see more, do more’, boosting patient volumes, diagnostic confidence, and workflow efficiency.”

These platforms are redefining efficiency in clinical ophthalmology, allowing more patients to be seen per day, with better insights, and fewer delays.

Toward the Future: Systemic Screening & Precision Health

Remidio’s mission continues to evolve. With validated AI for Diabetic Retinopathy, Glaucoma, and AMD, the company is also working on expanding screening capabilities into systemic conditions such as cardiovascular disease (CVD) and chronic kidney disease (CKD), leveraging the eye as a window into overall health. From outreach to in-clinic diagnostics, from retina to systemic health, Remidio’s dual brand strategy sets the stage for the next decade of transformation in eye care.